“It also allows us to invest in strengthening our clinical, regulatory and operational capabilities as we execute on key development milestones. Our focus is on generating high-quality clinical data that can meaningfully improve treatment options for patients with COPD.” EXPD-101 is designed to target neutrophilic inflammation, a mechanism Expedition regards as a key underlying driver of COPD across the disease spectrum. “COPD remains one of the leading causes of death worldwide, yet treatment options for many patients have changed relatively little over the past decade." As Expedition continues to move through the funding life cycle, Larson shared the firm’s immediate focus remains on executing its clinical strategy.